BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol. 2004;57:867-871. [PMID: 15280410 DOI: 10.1136/jcp.2003.015784] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
2 Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Med Oncol. 2011;28:1012-1016. [PMID: 20571936 DOI: 10.1007/s12032-010-9600-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chevallier P, Baudin G, Anty R, Guibal A, Chassang M, Avril L, Tran A. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagnostic and Interventional Imaging 2015;96:637-46. [DOI: 10.1016/j.diii.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
4 Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13:120-125. [PMID: 18305056 DOI: 10.1634/theoncologist.2007-0174] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 8.1] [Reference Citation Analysis]
6 Michaelis M, Michaelis R, Suhan T, Schmidt H, Mohamed A, Doerr HW, Cinatl J Jr. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion. FASEB J. 2007;21:81-87. [PMID: 17135367 DOI: 10.1096/fj.06-6779com] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
7 Guido M, Sarcognato S, Russo FP, Cardin R, Piciocchi M, Colloredo G, Farinati F. Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. Liver Int 2018;38:1770-6. [DOI: 10.1111/liv.13718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009;15:263-268. [PMID: 19672141 DOI: 10.1097/PPO.0b013e3181af5e35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Meriggi F, Zaniboni A. Gemox: A Widely Useful Therapy Against Solid Tumors-Review and Personal Experience. Journal of Chemotherapy 2013;22:298-303. [DOI: 10.1179/joc.2010.22.5.298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Zhu AX. New agents on the horizon in hepatocellular carcinoma. Ther Adv Med Oncol. 2013;5:41-50. [PMID: 23323146 DOI: 10.1177/1758834012458480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
11 Vertemati M, Moscheni C, Petrella D, Lamperti L, Cossa M, Gambacorta M, Goffredi M, Vizzotto L. Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathol Res Pract. 2012;208:240-244. [PMID: 22429827 DOI: 10.1016/j.prp.2012.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
12 Amarapurkar AD, Amarapurkar DN, Vibhav, Patel ND. Angiogenesis in chronic liver disease. Annals of Hepatology 2007;6:170-3. [DOI: 10.1016/s1665-2681(19)31924-6] [Cited by in Crossref: 27] [Article Influence: 1.8] [Reference Citation Analysis]
13 Liu Y, Lu T, Wang C, Li H, Xu K, Li P. Intravital assessment of angioarchitecture in rat hepatocellular nodules using in vivo fluorescent microscopy. Quant Imaging Med Surg 2019;9:1047-55. [PMID: 31367558 DOI: 10.21037/qims.2019.06.11] [Reference Citation Analysis]
14 Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2014; 20(12): 3087-3099 [PMID: 24696596 DOI: 10.3748/wjg.v20.i12.3087] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
15 Selitsky SR, Baran-Gale J, Honda M, Yamane D, Masaki T, Fannin EE, Guerra B, Shirasaki T, Shimakami T, Kaneko S, Lanford RE, Lemon SM, Sethupathy P. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep 2015;5:7675. [PMID: 25567797 DOI: 10.1038/srep07675] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 12.0] [Reference Citation Analysis]
16 Sacco R. Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma. Future Oncol. 2014;10:2073-2079. [PMID: 25396778 DOI: 10.2217/fon.14.92] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
17 Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39:493-502. [PMID: 22846866 DOI: 10.1053/j.seminoncol.2012.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
18 Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247-1256. [PMID: 20405329 DOI: 10.1245/s10434-010-0975-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
19 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 12.2] [Reference Citation Analysis]
20 Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. The Oncologist 2005;10:392-8. [DOI: 10.1634/theoncologist.10-6-392] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
21 Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma. J Gastrointest Cancer 2015;46:104-8. [PMID: 25645584 DOI: 10.1007/s12029-015-9684-5] [Reference Citation Analysis]
22 Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs. 2010;19:663-672. [PMID: 20367287 DOI: 10.1517/13543781003767426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
23 Elpek G&. Angiogenesis and liver fibrosis. World J Hepatol 2015; 7(3): 377-391 [PMID: 25848465 DOI: 10.4254/wjh.v7.i3.377] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
24 Bai RJ, Li JP, Ren SH, Jiang HJ, Liu XD, Ling ZS, Huang Q, Feng GL. A correlation of computed tomography perfusion and histopathology in tumor edges of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014;13:612-7. [PMID: 25475863 DOI: 10.1016/s1499-3872(14)60298-8] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898-1903. [PMID: 16622265 DOI: 10.1200/jco.2005.04.9130] [Cited by in Crossref: 282] [Cited by in F6Publishing: 106] [Article Influence: 17.6] [Reference Citation Analysis]
26 Chebib I, Shabani-rad MT, Chow MS, Zhang J, Gao Z. Microvessel Density and Clinicopathologic Characteristics in Hepatocellular Carcinoma with and without Cirrhosis. Biomark�Insights 2007;2:117727190700200. [DOI: 10.1177/117727190700200013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
27 Alkharsah KR. VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications. Int J Mol Sci. 2018;19. [PMID: 29865171 DOI: 10.3390/ijms19061642] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
28 Fornaro L, Vivaldi C, Caparello C, Sacco R, Rotella V, Musettini G, Luchi S, Baldini EE, Falcone A, Masi G. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol. 2014;10:285-304. [PMID: 24490614 DOI: 10.2217/fon.13.181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging 2013;30:887-92. [PMID: 24097332 DOI: 10.1007/s40266-013-0124-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
30 Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Front Immunol 2020;11:1037. [PMID: 32547550 DOI: 10.3389/fimmu.2020.01037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
31 Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009;49:1469-82. [PMID: 19235829 DOI: 10.1002/hep.22849] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 6.0] [Reference Citation Analysis]
32 Vrancken K, Vervaeke P, Balzarini J, Liekens S. Viruses as key regulators of angiogenesis. Rev Med Virol 2011;21:181-200. [PMID: 21538666 DOI: 10.1002/rmv.688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
33 Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. Eur J Radiol. 2013;82:e205-e211. [PMID: 23273822 DOI: 10.1016/j.ejrad.2012.12.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
34 Chau GY. Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome. World J Gastroenterol 2014; 20(35): 12473-12484 [PMID: 25253947 DOI: 10.3748/wjg.v20.i35.12473] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
35 Tan XP, Zhou K, Zeng QL, Yuan YF, Chen W. Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 35293607 DOI: 10.1007/s10238-022-00813-4] [Reference Citation Analysis]
36 Zhu AX. Successful targeted therapies for hepatocellular carcinoma: are we really getting there? Expert Review of Anticancer Therapy 2014;8:499-505. [DOI: 10.1586/14737140.8.4.499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Vrancken K, Paeshuyse J, Liekens S. Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother. 2012;22:159-170. [PMID: 22182803 DOI: 10.3851/imp1987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
39 Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N, Kanematsu T, Fujioka H. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res. 2012;172:116-122. [PMID: 20855083 DOI: 10.1016/j.jss.2010.07.057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
40 Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. J Comput Assist Tomogr 2019;43:206-13. [PMID: 30407241 DOI: 10.1097/RCT.0000000000000807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Tumanova UN, Shchegolev AI. Vascularization of hepatocellular carcinoma. Arkh patol 2015;77:50. [DOI: 10.17116/patol201577250-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Tazi el M, Essadi I, M'rabti H, Touyar A, Errihani PH. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci 2011;3:167-75. [PMID: 22540086 DOI: 10.4297/najms.2011.3167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
43 Paschoal JP, Bernardo V, Canedo NH, Ribeiro OD, Caroli-Bottino A, Pannain VL. Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression. BMC Cancer 2014;14:72. [PMID: 24507660 DOI: 10.1186/1471-2407-14-72] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
44 Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatol Int. 2013;7:4-12. [PMID: 26201617 DOI: 10.1007/s12072-012-9391-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
45 Shao YY, Hsieh MS, Wang HY, Li YS, Lin H, Hsu HW, Huang CY, Hsu CH, Cheng AL. Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. Oncotarget. 2017;8:86681-86692. [PMID: 29156827 DOI: 10.18632/oncotarget.21407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
46 Yang F, Zhao J, Liu C, Mao Y, Mu J, Wei X, Jia J, Zhang S, Xin X, Tan J. Superb microvascular imaging technique in depicting vascularity in focal liver lesions: more hypervascular supply patterns were depicted in hepatocellular carcinoma. Cancer Imaging 2019;19:92. [PMID: 31888768 DOI: 10.1186/s40644-019-0277-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
47 Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics. 2006;6:2865-2873. [PMID: 16586433 DOI: 10.1002/pmic.200500488] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 4.7] [Reference Citation Analysis]
48 Murakami K, Kasajima A, Kawagishi N, Ohuchi N, Sasano H. Microvessel density in hepatocellular carcinoma: Prognostic significance and review of the previous published work. Hepatol Res. 2015;45:1185-1194. [PMID: 25594920 DOI: 10.1111/hepr.12487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
49 Dohmen K, Shigematsu H, Irie K, Ishibashi H. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients. Hepatogastroenterology. 2003;50:2022-2027. [PMID: 14696457 DOI: 10.1016/j.ejca.2006.06.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
50 Gligorijević J, Djordjević B, Petrović A, Radirević A, Stojanović S. Expression of CD34 in cirrhotic liver--reliance to dedifferentiation. Vojnosanit Pregl 2010;67:459-62. [PMID: 20629423 DOI: 10.2298/vsp1006459g] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Wang Q, Zhong YJ, Yuan JP, Shao LH, Zhang J, Tang L, Liu SP, Hong YP, Firestone RA, Li Y. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med 2013;11:192. [PMID: 23961994 DOI: 10.1186/1479-5876-11-192] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
52 Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014;5:78-94. [PMID: 24393789 DOI: 10.18632/oncotarget.1569] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 10.0] [Reference Citation Analysis]
53 Benkheil M, Van Haele M, Roskams T, Laporte M, Noppen S, Abbasi K, Delang L, Neyts J, Liekens S. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer. Exp Cell Res. 2018;372:168-177. [PMID: 30287142 DOI: 10.1016/j.yexcr.2018.09.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
54 Luo LM, Xia H, Shi R, Zeng J, Liu XR, Wei M. The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma. Oncol Lett 2017;14:7077-84. [PMID: 29344137 DOI: 10.3892/ol.2017.7106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008;112:250-259. [PMID: 18041064 DOI: 10.1002/cncr.23175] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 7.6] [Reference Citation Analysis]